Neurotherapeutics

, Volume 7, Issue 3, pp 241–249 | Cite as

Tetrahydrobiopterin as a novel therapeutic intervention for autism

  • Richard E. Frye
  • Lynne C. Huffman
  • Glen R. Elliott
Review Article

Summary

Tetrahydrobiopterin (BH4) is an essential cofactor for several critical metabolic pathways that have been reported to be abnormal in autism spectrum disorder (ASD). In addition, the cerebrospinal fluid concentration of BH4 is reported to be depressed in children with ASD. Over the past 25 years, several clinical trials have suggested that treatment with BH4 improves ASD symptomatology in some individuals. Two ongoing clinical protocols may help further define the efficacy of BH4 treatment in children with ASD. First, children with ASD who had low concentrations of cerebrospinal fluid or urine pterins were treated in an open-label manner with 20 mg/kg per day of BH4. The majority of children (63%) responded positively to treatment, with minimal adverse events (AEs). Second, a double-blind placebo-controlled study examining the efficacy of 20 mg/kg per day of BH4 treatment in children with ASD is currently underway. Safety studies from the commercially available forms of BH4 document the low incidence of AEs, particularly serious AEs. Studies have also documented the ability of BH4 to cross the blood-brain barrier. Based on the importance of BH4 in neurodevelopmental metabolic pathways, the safety of BH4 treatment, and the evidence for a therapeutic benefit of BH4 treatment in children with ASD, we conclude that BH4 represents a novel therapy for ASD, one that may gain wider use after further clinical studies have established efficacy and treatment guidelines.

Key Words

Tetrahydrobiopterin autism spectrum disorder monoamine neurotransmitters nitric oxide treatment 

References

  1. 1.
    Rogers SJ, Ozonoff S. Behavioral, educational, and developmental treatments of autism. In: Moldin SO, Rubenstein JLR, editors. Understanding autism: from basic neuroscience to treatment. Boca Raton, FL: CRC Taylor & Francis, 2006: 443–473.Google Scholar
  2. 2.
    Buitelaar J. Why have drug treatments been so disappointing? In: Bock G, Goode J, editors. Autism: neural basis and treatment possibilities. New York: Novartis Foundation, 2003: 235–249.CrossRefGoogle Scholar
  3. 3.
    McDougle CJ, Posey DJ, Stigler KA. Pharmacological Treatments. In: Moldin SO, Rubenstein JLR, editors. Understanding autism: from basic neuroscience to treatment. Boca Raton, FL: CRC Taylor & Francis, 2006: 417–442.Google Scholar
  4. 4.
    Vitiello B, Wagner A. Government initiatives in autism clinical trials. CNS Spectr 2004;9: 66–73.PubMedGoogle Scholar
  5. 5.
    Thöny B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000;347 Pt 1: 1–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993;34: 10–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Tani Y, Fernell E, Watanabe Y, Kanai T, Långström B. Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett 1994;181: 169–172.CrossRefPubMedGoogle Scholar
  8. 8.
    Dietert RR, Dietert JM. Potential for early-life immune insult including developmental immunotoxicity in autism and autism spectrum disorders: focus on critical windows of immune vulnerability. J Toxicol Environ Health B Crit Rev 2008;11: 660–680.PubMedGoogle Scholar
  9. 9.
    Castellani ML, Conti CM, Kempuraj DJ, et al. Autism and immunity: revisited study. Int J Immunopathol Pharmacol 2009;22: 15–19.PubMedGoogle Scholar
  10. 10.
    Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005;17: 485–495.CrossRefPubMedGoogle Scholar
  11. 11.
    James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80: 1611–1617.PubMedGoogle Scholar
  12. 12.
    Deth R, Muratore C, Benzecry J, Power-Chamitsky VA, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29: 190–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007;17: 434–447.CrossRefPubMedGoogle Scholar
  14. 14.
    Kem JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006;9: 485–499.CrossRefGoogle Scholar
  15. 15.
    Koshimura K, Murakami Y, Tanaka J, Kato Y. Self-protection of PC12 cells by 6R-tetrahydrobiopterin from nitric oxide toxicity. J Neurosci Res 1998;54: 664–672.CrossRefPubMedGoogle Scholar
  16. 16.
    Kojima S, Ona S, Iizuka I, Arai T, Mori H, Kubota K. Antioxidative activity of 5,6,7,8-tetrahydrobiopterin and its inhibitory effect on paraquat-induced cell toxicity in cultured rat hepatocytes. Free Radic Res 1995;23: 419–430.CrossRefPubMedGoogle Scholar
  17. 17.
    McDougle CJ, Kresch LE, Goodman WK, et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995;152: 772–777.PubMedGoogle Scholar
  18. 18.
    Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 2006;67: 407–414.CrossRefPubMedGoogle Scholar
  19. 19.
    Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006;16: 181–186.CrossRefPubMedGoogle Scholar
  20. 20.
    Soorya L, Kiarashi J, Hollander E. Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008;17: 753–771 viii.CrossRefPubMedGoogle Scholar
  21. 21.
    Mulder EJ, Anderson GM, Kema IP, et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry 2004;43: 491–499.CrossRefPubMedGoogle Scholar
  22. 22.
    Bramham J, Ambery F, Young S, et al. Executive functioning differences between adults with attention deficit hyperactivity disorder and autistic spectrum disorder in initiation, planning and strategy formation. Autism 2009;13: 245–264.CrossRefPubMedGoogle Scholar
  23. 23.
    Corbett BA, Constantine LJ, Hendren R, Rocke D, Ozonoff S. Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res 2009;166: 210–222.CrossRefPubMedGoogle Scholar
  24. 24.
    Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2009;39: 395–404.CrossRefPubMedGoogle Scholar
  25. 25.
    Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006;16: 611–619.CrossRefPubMedGoogle Scholar
  26. 26.
    Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16: 599–610.CrossRefPubMedGoogle Scholar
  27. 27.
    Nakane Y, Naruse H, Hayashi T, Takesada M, Yamazaki K. Clinical effect of R-THBP on Infantile Autism. In: Naruse H, Ornitz E, editors. Neurobiology of infantile autism: Proceedings of the International Symposium on Neurobiology of Infantile Autism, Tokyo, 10–11 November 1990. New York: Elsevier Science Publishers, 1992: 337–349.Google Scholar
  28. 28.
    Naruse H, Hayashi T, Takesada M. A preliminary study on clinical effect of tetrahydrobiopterin in infantile autism [In Japanese]. In: Reports in 1983 for New Drug Development. Tokyo: Ministry of Health and Welfare, 1984: 71–81.Google Scholar
  29. 29.
    Naruse H, Hayashi T, Takesada M, Nakane Y, Yamazaki K. Metabolic changes in aromatic amino acids and monoamines in infantile autism and development of new treatment related to the findings [In Japanese]. No to Hattatu 1989;21: 181–189.Google Scholar
  30. 30.
    Naruse H, Hayashi T, Takesada M, et al. Therapeutic effect of tetrahydrobiopterin in infantile autism. Proc Jpn Acad 1987;63B: 231–233.CrossRefGoogle Scholar
  31. 31.
    Naruse H, Takesada M, Nakane Y, et al. Clinical evaluation of R-tetrahydrobiopterin (SUN 0588) on infantile autism: a double-blind comparative study using placebo as a control [Japanese]. Rinsho Iyaku 1990;6: 1343–1368.Google Scholar
  32. 32.
    Naruse H, Takesada M, Nagahata M, Kazamatsuri H, Nakane Y, Yamazaki K. An open clinical study of sapropterin hydrochloride (R-tetrahydrobiopterin SUN 0588) in infantile autism: clinical study using a Rating Scale for Abnormal Behaviors in Children [Japanese]. Rinsho Iyaku 1990;6: 1859–1875.Google Scholar
  33. 33.
    Nagahata M, Kazamatsuri H, Naruse H, et al. Clinical evaluation of sapropterin hydrochloride (R-THBP. SUN 0588) on infantile autism: a multicenter cooperative study [Japanese]. Rinsho Iyaku 1990;6: 1877–1899.Google Scholar
  34. 34.
    Nakane Y, Asuo T, Shimogawa S, Fujiwara T, Kawabata Y, Kubota J. Clinical efficacy and effects on physical development of long-term treatment of R-tetrahydrobiopterin (R-THBP, SUN 0588) for autism[Japanese]. Kiso to Rinsho 1990;24: 4579–4598.Google Scholar
  35. 35.
    Takesada M, Naruse H, Nagahata M. An open clinical study of sapropterin hydrochloride (R-tetrahydrobiopterin, R-THBP) in infantile autism: clinical effects and long-term follow-up. In: Naruse H, Ornitz E, editors. Neurobiology of infantile autism: Proceedings of the International Symposium on Neurobiology of Infantile Autism, Tokyo, 10–11 November 1990. New York: Elsevier Science Publishers, 1992: 355–358.Google Scholar
  36. 36.
    Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 2005;25: 485–489.CrossRefPubMedGoogle Scholar
  37. 37.
    Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism—clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997;39: 313–318.CrossRefPubMedGoogle Scholar
  38. 38.
    Miller L, Insel T, Scheinin M, et al. Tetrahydrobiopterin administration to rhesus macaques: its appearance in CSF and effect on neurotransmitter synthesis. Neurochem Res 1986;11: 291–298.CrossRefPubMedGoogle Scholar
  39. 39.
    Kapatos G, Kaufman S. Peripherally administered reduced pterins do enter the brain. Science 1981;212: 955–956.CrossRefPubMedGoogle Scholar
  40. 40.
    Brand MP, Hyland K, Engle T, Smith I, Heales SJ. Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse. J Neurochem 1996;66: 1150–1156.CrossRefPubMedGoogle Scholar
  41. 41.
    Canevari L, Land JM, Clark JB, Heales SJ. Stimulation of the brain NO/cyclic GMP pathway by peripheral administration of tetrahydrobiopterin in the hph-1 mouse. J Neurochem 1999;73: 2563–2568.CrossRefPubMedGoogle Scholar
  42. 42.
    Thöny B, Calvo AC, Scherer T, et al. Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. J Neurochem 2008;106: 672–681.CrossRefPubMedGoogle Scholar
  43. 43.
    Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB. Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. Pediatrics 1982;70: 376–380.PubMedGoogle Scholar
  44. 44.
    Ferraris S, Guardamagna O, Bonetti G, et al. Fate of peripherally administered tetrahydrobiopterin in congenital tetrahydrobiopterin deficiency. In: Curtius HC, Blau N, Levine RA, editors. Unconjugated pterins and related biogenic amines: proceedings of the first international workshop, Flims, Switzerland, February 28–March 7, 1987. New York: Walter de Gruyter, 1987: 283–292.Google Scholar
  45. 45.
    al Aqeel A, Ozand PT, Gascon GG, Hughes H, Reynolds CT, Subramanyam SB. Response of 6-pyruvoyl-tetrahydropterin synthase deficiency to tetrahydrobiopterin. J Child Neurol 1992;7 Suppl: S26-S30.CrossRefPubMedGoogle Scholar
  46. 46.
    BioMarin Pharmaceutical Inc. Investigator’s brochure. Version 4.0. Novato, CA: BioMarin Pharmaceutical, 2008.Google Scholar
  47. 47.
    Tegenge MA, Bicker G. Nitric oxide and cyclic GMP signal transduction positively regulates the motility of human neuronal precursor (NT2) cells. J Neurochem 2009;110: 1828–1841.CrossRefPubMedGoogle Scholar
  48. 48.
    Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008;27: 2783–2802.CrossRefPubMedGoogle Scholar
  49. 49.
    Anastasiadis PZ, Bezin L, Imerman BA, Kuhn DM, Louie MC, Levine RA. Tetrahydrobiopterin as a mediator of PC12 cell proliferation induced by EGF and NGF. Eur J Neurosci 1997;9: 1831–1837.CrossRefPubMedGoogle Scholar
  50. 50.
    Koshimura K, Miwa S, Lee K, Fujiwara M, Watanabe Y. Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-l-erythro-5,6,7,8-tetrahydrobiopterin. J Neurochem 1990;54: 1391–1397.CrossRefPubMedGoogle Scholar
  51. 51.
    Mataga N, Imamura K, Watanabe Y. L-Threo-3,4-dihydroxyphenylserine enhanced ocular dominance plasticity in adult cats. Neurosci Lett 1992;142: 115–118.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Richard E. Frye
    • 1
  • Lynne C. Huffman
    • 2
    • 3
  • Glen R. Elliott
    • 2
    • 3
    • 4
  1. 1.Division of Child and Adolescent Neurology and The Children’s Learning Institute, Department of PediatricsUniversity of Texas Health Science Center at HoustonHouston
  2. 2.The Children’s Health CouncilPalo Alto
  3. 3.Stanford University School of MedicinePalo Alto
  4. 4.University of California San FranciscoSan Francisco

Personalised recommendations